Biothera’s Imprime PGG in combination with cetuximab, carboplatin and paclitaxel has met all the endpoints in a Phase II non small cell lung cancer clinical trial.
Imprime PGG is an immunomodulatory drug, used as a treatment for cancer.
The open label multicentre randomised trial enrolled 90 patients to evaluate the safety and efficacy of Imprime PGG along with cetuximab and a standard chemotherapy regimen (carboplatin and paclitaxel) compared to cetuximab alone with the same chemotherapy.
The aim of the study is to assess the anti-tumour effects of Imprime PGG with cetuximab and standard chemotherapy, based on overall response rate as evaluated by the RECIST trial.
In pre-clinical cancer models, Imprime PGG has been found to reduce tumour growth and enhance long-term survival by killing neutrophils.
Imprime PGG is being investigated in a Phase III trial in KRAS wild-type colorectal cancer and several Phase II clinical trials in non small cell lung cancer and chronic lymphocytic leukaemia.
